Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints

TNF-Blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints: Randomized, Double Blind, Placebo-Controlled Cross-Over Study to Evaluate the Efficacy of Adalimumab 40 mg SC Every Other Week in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints

Patients will be randomized into two groups (1/1) during one year:

• 40 mg adalimumab subcutaneously (sc) every other week
• placebo

The effect on x-rays and clinical parameters will be evaluated.

Inclusion Criteria:

• Clear erosive image on x-ray of at least one interphalangeal finger joint